5 Best Russell 2000 Stocks to Invest In According to Hedge Funds

3. Tyra Biosciences, Inc. (NASDAQ:TYRA)

Number of Hedge Fund Holders: 40

On May 19, Wolfe Research initiated Tyra Biosciences, Inc. (NASDAQ:TYRA) with a Peer Perform rating and no price target. The analyst stated dabogratinib could “achieve the CR bar for LR IR NMIBC” while remaining “on the fence” pending safety de-risking.

On May 13, Tyra Biosciences, Inc. (NASDAQ:TYRA) reported Q1 results, advancing its “dabogratinib 3×3” strategy, dosing the first LG-UTUC patient in SURF303, and targeting initial results in 2027. Cash stood at $383.5 million, funding operations into 2H 2028.

The company posted a net loss of $39.3 million from $28.1 million a year earlier and raised R&D expenses to $33.5 million.

CEO Todd Harris said the firm “continues to advance with steady progress,” flagging multiple data readouts in 2026.

Chief Medical Officer Doug Warner noted dabogratinib may “represent a meaningful shift” in treatment, pointing to the Phase 2 studies across three indications.

Tyra Biosciences, Inc. (NASDAQ:TYRA) is a precision oncology firm that develops purpose-built treatments to overcome tumor resistance and improve cancer patients’ outcomes.

1281292 - 11759070 - 1